Mary Wheeler, BioRock Ventures - 2019…There Were 20 $1B Biopharma IPOs…We Just Don’t Call Them Unicorns Because They’re Not That Rare | #217

The Meb Faber Show - Better Investing

The Idea Farm

Investing, Management, Business

4.8 • 978 Ratings

🗓️ 4 May 2020

⏱️ 51 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

In episode 217 we welcome our guest, Mary Wheeler, Founding Managing Director of BioRock Ventures. In today’s episode, we get into biotech and venture capital. We cover Mary’s deep background that ultimately influenced her investment focus on biotech. We cover her fund, BioRock Ventures, investing in biopharma startups, her core investment criteria, and keeping an eye out for companies serving unmet need areas. We touch on some key differences between biotech focused VC investing vs. other areas of VC. Mary even shares some insight into a company in her portfolio that has focused resources on potential COVID19 applications. All this and more in episode 217 with BioRock Ventures’ Mary Wheeler. Learn more about your ad choices. Visit megaphone.fm/adchoices

Transcript

Click on a timestamp to play from that location

0:00.0	Welcome to the Mebb Faver Show, where the focus is on helping you grow and preserve your wealth.
0:11.0	Join us as we discuss the craft of investing and
0:13.5	uncover new and profitable ideas all to help you grow wealthier and wiser.
0:17.2	Better investing starts here.
0:18.8	Met Faber is the co-founder and chief investment officer at Cambria Investment Management.
0:23.3	Did it industry regulations, he will not discuss any of Cambry's funds on this podcast.
0:27.2	All opinions expressed by podcast participants are solely their own opinions and do not reflect the opinion of
0:31.2	Cambria Investment Management or its affiliates.
0:33.4	For more information, visit Cambria Investments.com.
0:35.6	What's up, podcast listeners, another great show for you today.
0:42.2	Our guest is founding managing director of Bio Rock Ventures, a Silicon Valley-based life
0:47.9	sciences VC fund investing in startups developing
0:54.5	novel drugs to treat disease.
0:55.5	and the portfolio even includes a startup developing a COVID treatment.
0:59.2	Mary has over 20 years experience in biotech companies of all sizes from sea level to
1:04.2	M&A deals licensing and strategy roles places like J&J and forests now Alargan and
1:10.0	also as a startup founder she's advised several dozen early stage ventures as well.
1:15.0	She's got an MBA from MIT Sloan, a PhD from Princeton,
1:18.0	and a BA from Yale.
1:19.3	Lordy, she is a Kaufman fellow too. In today's episode, we get into biotech and VC.
1:25.0	We cover our guest's deep background that ultimately influence her investment focus on biotech.
1:29.0	We cover fun, Biorock Ventures, investing in Bio-Farmer startups for core investing criteria
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Idea Farm, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Idea Farm and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.